Understanding the stability of zeolitic imidazolate framework-8 (ZIF-8) under physiological conditions is critical in biotechnology and biomedicine for biosensing, biocatalysis, and drug delivery.

No abstract

Zeolitic imidazolate framework (ZIF) biocomposites show the capacity to protect and deliver biotherapeutics. To date, the progress in this research area is based on laboratory batch methods. Now, the first continuous flow synthetic method is presented for the encapsulation of a model protein (bovine serum albumin, BSA) and a clinical therapeutic (α1‐antitrypsin, AAT) in ZIF‐8. The in situ kinetics of nucleation, growth, and crystallization of BSA@ZIF‐8 were studied by small‐angle X‐ray scattering. By controlling the injection time of ethanol, the particle growth could be quenched by ethanol‐induced crystallization from amorphous particles to ZIF‐8 crystals. The particle size of the biocomposite was tuned in the 40–100 nm range by varying residence time prior to introduction of ethanol. As a proof‐of‐concept, this procedure was used for the encapsulation of AAT in ZIF‐8. Upon release of the biotherapeutic from the composite, the trypsin inhibitor function of AAT was preserved.

Processing oriented metal–organic frameworks (MOFs) as thin films is a key challenge for their application to device fabrication. However, typical fabrication methods cannot generate precisely oriented crystals on commercially relevant scales (i.e., cm2). This limits access to applications that require anisotropic functional properties (e.g., separation, optics, and electronics). Currently, highly oriented copper‐based MOFs are synthesized via the addition of the organic MOF component to an ethanolic solution of manually aligned Cu(OH)2 nanobelt films. In this work, the optimization of a semi‐automatic method for the fabrication of precisely oriented MOF films that affords a 100% yield of high quality ceramic films at the centimeter scale is reported. This improved fabrication protocol will facilitate the progress of heteroepitaxially grown MOFs for molecular separators and micro‐opto‐electronic devices.

Synthesis of covalent organic framework (COF) thin films on different supports with high crystallinity and porosity is crucial for their potential applications. We have designed a new synchronized methodology, residual crystallization (RC), to synthesize sub 10 nm COF thin films. These residual crystallized COF thin films showcase high surface area, crystallinity, and conductivity at room temperature. We have used interfacial crystallization (IC) as a rate-controlling tool for simultaneous residual crystallization. We have also diversified the methodology of residual crystallization by utilizing two different crystallization pathways: fiber-to-film (F−F) and sphere-to-film (S−F). In both cases, we could obtain continuous COF thin films with high crystallinity and porosity grown on various substrates (the highest surface area of a TpAzo COF thin film being 2093 m 2 g −1 ). Precise control over the crystallization allows the synthesis of macroscopic defect-free sub 10 nm COF thin films with a minimum thickness of ∼1.8 nm. We have synthesized two COF thin films (TpAzo and TpDPP) using F−F and S−F pathways on different supports such as borosilicate glass, FTO, silicon, Cu, metal, and ITO. Also, we have investigated the mechanism of the growth of these thin films on various substrates with different wettability. Further, a hydrophilic support (glass) was used to grow the thin films in situ for four-probe system device fabrication. All residual crystallized COF thin films exhibit outstanding conductivity values. We could obtain a conductivity of 3.7 × 10 −2 mS cm −1 for the TpAzo film synthesized by S−F residual crystallization.

Fundamental knowledge on the intrinsic timescale of structural transformations in photo-switchable Metal-Organic Framework films, is crucial to tune their switching performance and to facilitate their applicability as stimuli-responsive materials. In...

to be extended from antibody-based sensing to diagnostic and therapeutic applications.

Zeolitic imidazolate framework (ZIF) biocomposites show the capacity to protect and deliver biotherapeutics. To date, the progress in this research area is based on laboratory batch methods. Now, the first continuous flow synthetic method is presented for the encapsulation of a model protein (bovine serum albumin, BSA) and a clinical therapeutic (α1‐antitrypsin, AAT) in ZIF‐8. The in situ kinetics of nucleation, growth, and crystallization of BSA@ZIF‐8 were studied by small‐angle X‐ray scattering. By controlling the injection time of ethanol, the particle growth could be quenched by ethanol‐induced crystallization from amorphous particles to ZIF‐8 crystals. The particle size of the biocomposite was tuned in the 40–100 nm range by varying residence time prior to introduction of ethanol. As a proof‐of‐concept, this procedure was used for the encapsulation of AAT in ZIF‐8. Upon release of the biotherapeutic from the composite, the trypsin inhibitor function of AAT was preserved.